Priority Review for Tesaro's niraparib

Tesaro Inc. (NASDAQ:TSRO) said FDA accepted and granted Priority Review to an NDA for niraparib (MK-4827) to treat recurrent epithelial ovarian, fallopian

Read the full 229 word article

User Sign In